玻璃体内氟轻松植入剂治疗后眼压变化的真实世界研究
ILUVIEN注册安全性研究是一项多中心、开放标签、观察性研究,收集按欧洲标签要求使用0.2 µg/日氟轻松植入剂治疗慢性糖尿病性黄斑水肿患者的真实世界数据。短期cDMO患者视力增益大于长期cDMO患者。
要点
- FAc植入后平均眼压保持正常,76.7%患者无需降眼压治疗。
- 短期cDMO患者视力增益大于长期cDMO患者,支持早期治疗。
核心结论
- FAc植入剂在真实世界中显示出良好的安全性和有效性,并证明早期FAc治疗有益。
研究设计与样本
- ILUVIEN注册安全性研究为正在进行的多中心、开放标签、观察性研究,收集按欧洲标签要求治疗患者的真实世界数据。
- 本次分析纳入慢性糖尿病性黄斑水肿(cDMO,即尽管治疗仍持续或复发的DMO)患者,数据收集至2017年3月6日。
主要发现
- 总体人群平均眼压在整个随访期间保持在正常范围。
- 76.7%患者在接受FAc植入后无需降眼压治疗。
- 总体平均视力从基线51.9个字母增至第12个月55.6个字母,末次观察显著增加2.9个字母。
- 短期cDMO患者比长期cDMO患者获得更大的视力增益。
关键数值与推荐
- FAc植入剂剂量为0.2 µg/日。
- 平均视力从基线51.9个字母增至第12个月55.6个字母,末次观察显著增加2.9个字母。
临床怎么用
- 对于慢性糖尿病性黄斑水肿患者,FAc植入剂可作为治疗选择,且早期治疗可能带来更大视力获益。
- 使用FAc植入剂时需监测眼压,但多数患者无需降眼压治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The ILUVIEN Registry Safety Study is an ongoing, multicentre, open-label, observational study collecting real-world data on the safety and effectiveness of the 0.2 µg/day fluocinolone acetonide (FAc) implant in patients treated according to the European label requirements. METHODS: Patients included in this analysis were treated for the licensed indication of chronic diabetic macular oedema (cDMO; that is, DMO that persists or recurs despite treatment). Data presented in the current analysis were collected from patient records up to 6 March 2017. Visual acuity (VA) data, including mean change in VA over time and at last observation, intraocular pressure (IOP) over the course of the study, IOP events, use of IOP-lowering therapy and cup:disc ratio were analysed. Information on additional DMO treatments post-FAc implant was also captured. RESULTS: Five hundred and sixty-three patients (593 eyes) were enrolled on the study. Mean IOP for the overall population remained within the normal range throughout follow-up and 76.7% of patients did not require IOP-lowering therapy following treatment with the FAc implant. Sixty-nine per cent of eyes did not require additional DMO treatments. Mean VA in the overall population increased from 51.9 letters at baseline to 55.6 letters at month 12, with a significant increase of 2.9 letters at last observation. Patients with short-term cDMO experienced greater VA gains than those with long-term cDMO. CONCLUSIONS: The results of this analysis are comparable with those of other studies, including the Fluocinolone Acetate for Macular Edema study. The study reinforces the good safety and effectiveness profile of FAc, and demonstrates the benefit of early FAc treatment.
引用
- Chakravarthy U, Taylor SR, Koch FHJ, et al. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2018. PMID: 30242062. doi:10.1136/bjophthalmol-2018-312284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。